Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen, Alkermes Settle Patent Suit with Teva on Vumerity Copies

Oct. 11, 2021, 3:17 PM

Biogen and Alkermes had claimed that Teva’s proposed generic version of Vumerity infringes three patents for the multiple sclerosis drug that Alkermes licenses exclusively to Biogen.

  • No details provided in stipulation and proposed order of dismissal, approved Friday in federal court in Wilmington, Delaware
  • Patents cover drug’s active ingredient, diroximel fumarate, and its use in treating MS, and expire in September 2033: FDA Orange Book
  • Biogen has predicted $1 billion peak-sales potential for Vumerity, though Bloomberg Intelligence analyst Marc Engelsgjerd said July 22that reaching that figure “seems a tall order”
  • EARLIER: Biogen Target Slashed At Guggenheim as Aduhelm ...